All News

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction …

How a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.…

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of t…

…

Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …

This analysis explores recent actions the Trump administration has taken to limit youth access to gender-affir…

This brief explains current Medicaid cost sharing rules and changes made to cost sharing rules by the 2025 rec…

The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug i…

London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating …

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ord…

48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.…

This tracker examines Executive Actions taken by the Trump administration that have the potential to impact LG…

A UCSF team has submitted an application to the FDA seeking approval for a small trial of in utero gene therap…

…

Last week at our biopharma and healthcare summit with the Financial Times, I was asked during one of our break…

With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now t…

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone syntha…

Here at Drug Channels, we’ve been closely tracking the evolution of the pharmacy benefit management (PBM) indu…

It's part of Democrats' strategy to focus on health care affordability and access in drawing contrasts with Re…

Already tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early brea…

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on…